Pathos AI joins BMS and Tempus on neurological drug development

The companies plan to combine clinical data and artificial-intelligence tools to support drug development. Pathos also raised $237 million in a Series E round led by Bristol Myers Squibb, valuing the company at about $3 billion.

Reuters noted that the partners did not disclose detailed timelines, the exact tools to be deployed or how responsibilities will be divided. Those unanswered points will determine how quickly the collaboration produces testable drug candidates.